Return to search results.
Complete title: A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
|Research Study Number||20121671|
|Principal Investigator||Scott Tykodi, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Kidney Cancer; Renal Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.